2023 Mark Foundation Endeavor Award The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts. $3M / 3 years. LOI due July 13, 2022. Mark Foundation Non-Federal Basic Science Clinical Research Translational Research
FY22 Pancreatic Cancer Research Program (PCARP) The DoD Congressionally Directed Medical Research Programs: FY22 PCARP is currently accepting applications for two award mechanisms: Idea Development Award and Translational Research Partnership Award. Preproposal due July 8, 2022. Department of Defense (DoD) Federal Basic Science Translational Research Early Career
Notice of Special Interest: Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy NOT-CA-22-063. Multiple deadlines and participating Institutes/Centers. The overall goal of this Notice of Special Interest (NOSI) is to promote mechanistic research aimed at better understanding the pathophysiology of immune-related adverse events (irAEs). It is anticipated that the mechanistic research supported through this NOSI will build the foundational knowledge which will ultimately lead to better strategies to predict, prevent and/or ameliorate toxicities that can arise as a consequence of current immunotherapeutic regimens, and improve treatment outcomes. The proposed research can be basic or translational but should be focused on revealing the mechanisms underlying irAEs. Single investigators and/or multidisciplinary teams with relevant expertise in the research area proposed and/or patient characterization and selection are encouraged to apply. National Institutes of Health (NIH) Federal Basic Science Translational Research
FY22 Kidney Cancer Research Program (KCRP) The DoD Congressionally Directed Medical Research Programs: FY22 KCRP is currently accepting applications for four award mechanisms: Idea Development Award, Translational Research Partnership Award, Concept Award, and Postdoctoral Clinical Fellowship Award. Preproposals or LOIs are due June 2, 2022 or June 23, 2022. Department of Defense (DoD) Federal Early Career Basic Science Translational Research
Notice of Special Interest: Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer NOT-CA-22-085. Multiple deadlines and participating Institutes/Centers. Earliest due date 6/5/2022. The purpose of this Notice of Special Interest (NOSI) is to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms. National Institutes of Health (NIH) Federal Basic Science Translational Research
Research Projects in Physical Sciences-Oncology (U01-Clinical Trial Optional) PAR-22-147. $400K/year (5 years). Earliest submission-June 8, 2022. This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the Physical Sciences-Oncology Network (PS-ON) is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research. National Institutes of Health (NIH) Federal Basic Science Translational Research
NIH Director’s Pioneer Award Program (DP1-Clinical Trial Optional) RFA-RM-22-018. $700K/year (5 years). Application due 9/9/2022. The NIH Director’s Pioneer Award Program supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation’s research workforce. Thus, individuals from all backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. The NIH Director’s Pioneer Award is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. National Institutes of Health (NIH) Federal Basic Science Translational Research Clinical Research
NIH Director’s New Innovator Award Program (DP2-Clinical Trial Optional) RFA-RM-22-019. $1.5M/5 years. Application due 8/19/2022. The NIH Director’s New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. The NIH Director's New Innovator Award Program complements other ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators. The NIH Director’s New Innovator Award Program is a component of the High-Risk, High-Reward Research (HRHR) Program of the NIH Common Fund. National Institutes of Health (NIH) Federal Basic Science Translational Research Early Career
Pediatric Immunotherapy Network (PIN) (U01-Clinical Trial Optional) RFA-CA-22-016. $450K/year (5 years). LOI due 8/27/2022. Application due 9/27/2022. Pre-application webinar on July 14, 2022 (pre-registration required). Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to solicit applications for the Pediatric Immunotherapy Network (PIN). The overall goal of this FOA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities focused on pediatric solid tumors (e.g., mechanisms of immune evasion, development of pre-clinical models, discovery and validation of novel therapeutic targets, development of novel pediatric immunotherapy agents and treatment approaches such as cancer vaccines, cellular therapy, and combinations with immunotherapy agents. Successful applicants will become members of the Pediatric Immunotherapy Network (PIN), which will address current challenges in pediatric cancer immunotherapy and accelerate the pace at which effective immunotherapies are realized for pediatric solid tumors. National Institutes of Health (NIH) Federal Basic Science Translational Research Clinical Research
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01-Clinical Trial Optional) PAR-22-131. Multiple deadlines. Earliest application due 10/5/2022. This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that integrate imaging, biomarkers, digital pathomics, glycomics, metabolomics, other omic information and/or meta data obtained from platforms including but not limited to lower resolution diagnostic acquisitions and systemic biomarker results to high resolution single-cell analytics / imaging applied to the characterization of heterogeneous cell populations within tumor for improving current approaches for: (1) the early detection of organ confined premetastatic aggressive cancer, and, (2) identifying precancerous lesions associated with the development of a subsequent lethal phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions by improving detection sensitivity and specificity of integrated multiparametric platforms. For example, N-dimensional co-registered, cross-correlated imaging data integrated with multiplexed biomarker results and/or digital pathomics, glycomics, or metabolomic imaging using analytic strategies such as artificial intelligence or virtual reality visualization techniques. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of potentially lethal cancer versus non-lethal disease, (2) minimize/better manage overdiagnosis and (3) reduce false positives and false negatives. National Institutes of Health (NIH) Federal Clinical Research Translational Research